Skip to content
Inciteful Med

Living with Sarcoidosis: Survivorship and Long-Term Care

Last updated:

Living with sarcoidosis requires ongoing active surveillance to catch disease flares early. Essential monitoring includes regular pulmonary function tests (PFTs), annual eye exams, and yearly EKGs to prevent permanent organ damage and manage complications like fatigue and pulmonary fibrosis.

Key Takeaways

  • • Regular pulmonary function tests (PFTs) are critical to track lung health, with a 10% drop in FVC or DLCO often signaling a new disease flare.
  • • Annual eye exams and EKGs are essential because sarcoidosis can cause silent, symptom-free damage to the eyes and heart.
  • • Advanced complications like pulmonary fibrosis and pulmonary hypertension affect up to 25% of patients, making proactive screening vital for early intervention.
  • • Black individuals, particularly Black women, face higher risks of severe sarcoidosis and benefit from proactive monitoring at specialized care centers.
  • • Profound fatigue and scan anxiety are common but highly impactful symptoms that can be managed through multidisciplinary programs and psychological support.

Living with sarcoidosis is a marathon, not a sprint. For many, the journey shifts from the initial shock of diagnosis to a long-term phase of “active surveillance” [1]. While at least 5% of patients face life-threatening complications, the majority of people live full lives by working closely with their care team to catch “flares” before they cause permanent damage [2][3].

Your Long-Term Surveillance Concept

Because sarcoidosis can be “quiet” while it progresses, regular check-ups are essential even when you feel well [1][4]. While every patient is different, a standard monitoring concept often includes:

  • Breathing Tests (PFTs): Tracking your Forced Vital Capacity (FVC) and DLCO (diffusion) is the primary way to monitor your lungs [5]. A sudden drop of 10% in FVC (or a sustained 5% downward trend), or a 10% drop in DLCO, is often considered a sign that the disease is becoming active again [5][6].
  • Annual Eye Exams: Sarcoidosis can cause inflammation in the eyes (uveitis) without any symptoms, which can lead to vision loss if not caught early. Yearly screenings are a must [4][7].
  • Heart Monitoring: At a minimum, an annual EKG is the standard, essential first step to check for the electrical “red flags” of cardiac involvement [8].
  • Biomarkers: Your doctor may track blood markers like sIL-2R (soluble IL-2 receptor) or ACE (angiotensin-converting enzyme). While not perfect, a sudden rise in sIL-2R often correlates with a new “flare” [9][10].

Understanding Long-Term Risks

In about 20-25% of cases, sarcoidosis can become “advanced” [11]. Understanding these risks helps you stay proactive:

  • Pulmonary Fibrosis: This is permanent scarring of the lung tissue [2]. It is the leading cause of death in sarcoidosis, but modern antifibrotic medications are now helping to slow this process down [12][13].
  • Pulmonary Hypertension (SAPH): This occurs when high blood pressure develops in the lungs, often due to scarring [14]. It is a serious complication that can increase mortality risk significantly [15][16]. If you notice a sudden, major decrease in how far you can walk (the 6-minute walk test), ask your doctor about screening for SAPH [17][18].

Addressing Demographic Disparities

It is an uncomfortable but necessary truth that sarcoidosis does not affect everyone equally. In the United States, Black individuals—especially Black women—face significantly higher risks of severe disease [19][20].

  • Understanding the Statistics: While statistics showing higher mortality rates for Black patients can be frightening to read, these numbers largely reflect historical disparities in access to care, delayed diagnosis, and socioeconomic barriers [21][22].
  • Protecting Yourself: By seeking proactive monitoring, advocating for comprehensive screenings, and partnering with specialized Sarcoidosis Centers of Excellence, you can significantly improve your outcomes and protect your health against these risks [20][23].

The Psychological Toll: “Scan Anxiety” and Fatigue

The “invisible” symptoms of sarcoidosis often weigh the heaviest on quality of life [24][25].

  • Scan Anxiety: It is normal to feel deep dread before a scheduled CT scan or PFT. This “scanxiety” is a recognized part of living with a chronic, unpredictable disease [26].
  • Profound Fatigue: Over half of patients suffer from a level of exhaustion that doesn’t go away with rest [27]. This is often linked to Small Fiber Neuropathy (SFN), which can cause burning or tingling sensations [28][24].
  • Empowerment: Participating in multidisciplinary programs—which combine physical therapy with psychological support—has been shown to significantly improve both mood and fatigue levels [24][25]. Your mental health is just as important as your lung function.

Frequently Asked Questions

How often should I have my lungs checked if I have sarcoidosis?
Regular breathing tests, or PFTs, are the primary way to monitor your lungs. A drop of 10% in your Forced Vital Capacity (FVC) or DLCO is often a sign that the disease is becoming active again and requires medical attention.
Do I need eye and heart exams if I don't have symptoms?
Yes, even if you feel completely fine, sarcoidosis can cause inflammation in the eyes and heart without any noticeable symptoms. Yearly comprehensive eye exams and an annual EKG are essential to catch these issues before they cause permanent damage.
What are the long-term complications of sarcoidosis?
In about 20-25% of cases, sarcoidosis can lead to advanced complications like pulmonary fibrosis, which is scarring of the lungs, or pulmonary hypertension. Proactive monitoring helps detect these risks early so your care team can adjust treatments to slow the disease progression.
Why do I feel so exhausted all the time with sarcoidosis?
Profound fatigue affects over half of sarcoidosis patients and often does not improve with rest. This exhaustion is frequently linked to conditions like Small Fiber Neuropathy, which can also cause burning or tingling sensations in your body.
Who is at the highest risk for severe sarcoidosis?
In the United States, Black individuals, particularly Black women, face significantly higher risks of severe disease. Partnering with a specialized sarcoidosis center and staying proactive with regular comprehensive screenings can help protect your health and improve outcomes.

Questions for Your Doctor

  • • What is my personal 'baseline' for FVC and DLCO, and what specific percentage drop in these numbers would you consider a sign that my disease is progressing?
  • • Since I have sarcoidosis, how often should I be getting an EKG and a comprehensive eye exam, even if I feel fine?
  • • Based on my current Scadding stage and symptoms, what is my long-term risk for developing pulmonary hypertension (SAPH), and how are we screening for it?
  • • Can we discuss the demographic disparities in sarcoidosis outcomes? Given my background, are there specific 'red flags' or more frequent screenings I should be aware of?
  • • I’m experiencing significant fatigue and 'scan anxiety'—are there multidisciplinary programs or psychological supports you can refer me to?

Questions for You

  • • How do you feel in the weeks leading up to a scheduled scan or appointment? Are there specific strategies (like meditation or scheduling appointments for first thing in the morning) that help you manage that anxiety?
  • • Have you noticed any subtle 'invisible' changes, such as new tingling in your feet, increased drenching night sweats, or a sudden change in how far you can walk before getting winded?
  • • If you are a person of color, do you feel your medical team is being proactive enough in monitoring you for the more aggressive forms of the disease often seen in Black populations?
  • • Do you have a clear, written record of your 'best' breathing test numbers so you can compare them to your future results?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.

    Melani AS, Simona A, Armati M, et al.

    Pulmonary therapy 2021; (7(2)):309-324 doi:10.1007/s41030-021-00161-w.

    PMID: 34091831
  2. 2

    Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?

    Bączek K, Piotrowski WJ

    Frontiers in pharmacology 2024; (15()):1445923 doi:10.3389/fphar.2024.1445923.

    PMID: 39281278
  3. 3

    From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis.

    Bonham CA, Strek ME, Patterson KC

    Current opinion in pulmonary medicine 2016; (22(5)):484-91 doi:10.1097/MCP.0000000000000301.

    PMID: 27379967
  4. 4

    Clinical and Ophthalmological Characteristics and Therapeutic Management of Patients With Sarcoidosis.

    Llerenas-Aguirre KI, Taboada Moreno B, Orozco Gómez LP

    Cureus 2025; (17(10)):e93898 doi:10.7759/cureus.93898.

    PMID: 41059029
  5. 5

    Pulmonary Function in Pulmonary Sarcoidosis.

    Yao Q, Ji Q, Zhou Y

    Journal of clinical medicine 2023; (12(21)) doi:10.3390/jcm12216701.

    PMID: 37959167
  6. 6

    Decreased serpin C1 in extracellular vesicles predicts response to methotrexate treatment in patients with pulmonary sarcoidosis.

    Kraaijvanger R, Janssen Bonás M, Grutters JC, et al.

    Respiratory research 2024; (25(1)):166 doi:10.1186/s12931-024-02809-y.

    PMID: 38627696
  7. 7

    Role of screening for uveitis in subjects with sarcoidosis.

    Koh LHL, Sims JL, Pepin F, et al.

    Respiratory medicine 2024; (224()):107562 doi:10.1016/j.rmed.2024.107562.

    PMID: 38342356
  8. 8

    Optimizing routine screening for cardiac sarcoidosis through use of commonly available studies.

    Holtzclaw AW, Mrsic Z, Church TL, et al.

    Respiratory medicine 2021; (178()):106331 doi:10.1016/j.rmed.2021.106331.

    PMID: 33592573
  9. 9

    Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement.

    Thi Hong Nguyen C, Kambe N, Kishimoto I, et al.

    The Journal of dermatology 2017; (44(7)):789-797 doi:10.1111/1346-8138.13792.

    PMID: 28295528
  10. 10

    YKL-40, Soluble IL-2 Receptor, Angiotensin Converting Enzyme and C-Reactive Protein: Comparison of Markers of Sarcoidosis Activity.

    Uysal P, Durmus S, Sozer V, et al.

    Biomolecules 2018; (8(3)) doi:10.3390/biom8030084.

    PMID: 30154391
  11. 11

    Advanced Pulmonary Sarcoidosis.

    Gupta R, Baughman RP

    Seminars in respiratory and critical care medicine 2020; (41(5)):700-715 doi:10.1055/s-0040-1709495.

    PMID: 32777853
  12. 12

    Advanced sarcoidosis.

    Baughman RP, Wells A

    Current opinion in pulmonary medicine 2019; (25(5)):497-504 doi:10.1097/MCP.0000000000000612.

    PMID: 31365384
  13. 13

    Novel insights in fibrotic pulmonary sarcoidosis.

    Comes A, Sofia C, Richeldi L

    Current opinion in pulmonary medicine 2022; (28(5)):478-484 doi:10.1097/MCP.0000000000000893.

    PMID: 35838359
  14. 14

    Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.

    Zhang S, Tong X, Zhang T, et al.

    Frontiers in cardiovascular medicine 2021; (8()):809594 doi:10.3389/fcvm.2021.809594.

    PMID: 35111830
  15. 15

    Sarcoidosis-Associated Pulmonary Hypertension.

    Israël-Biet D, Pastré J, Nunes H

    Journal of clinical medicine 2024; (13(7)) doi:10.3390/jcm13072054.

    PMID: 38610818
  16. 16

    The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - A cohort study.

    Tiosano S, Versini M, Dar Antaki L, et al.

    Clinical immunology (Orlando, Fla.) 2019; (199()):57-61 doi:10.1016/j.clim.2018.12.012.

    PMID: 30543925
  17. 17

    Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.

    Shlobin OA, Kouranos V, Barnett SD, et al.

    The European respiratory journal 2020; (55(5)) doi:10.1183/13993003.01747-2019.

    PMID: 32139456
  18. 18

    The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.

    Gupta R, Baughman RP, Nathan SD, et al.

    Respiratory medicine 2022; (196()):106801 doi:10.1016/j.rmed.2022.106801.

    PMID: 35316723
  19. 19

    Disparities in Sarcoidosis Mortality by Region, Urbanization, and Race in the United States: A Multiple Cause of Death Analysis.

    Ogundipe F, Mehari A, Gillum R

    The American journal of medicine 2019; (132(9)):1062-1068.e3 doi:10.1016/j.amjmed.2019.03.048.

    PMID: 31047868
  20. 20

    Sarcoidosis Epidemiology: Race Matters.

    Hena KM

    Frontiers in immunology 2020; (11()):537382 doi:10.3389/fimmu.2020.537382.

    PMID: 33042137
  21. 21

    Predictors of Mortality in Pulmonary Sarcoidosis.

    Kirkil G, Lower EE, Baughman RP

    Chest 2018; (153(1)):105-113 doi:10.1016/j.chest.2017.07.008.

    PMID: 28728933
  22. 22

    Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple Systems.

    McGuire L, Brown R, Asimaki A

    Journal of cardiovascular translational research 2025; (18(6)):1893-1901 doi:10.1007/s12265-025-10700-4.

    PMID: 40996589
  23. 23

    Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study.

    Hadi YB, Lakhani DA, Naqvi SFZ, et al.

    Respiratory medicine 2021; (187()):106538 doi:10.1016/j.rmed.2021.106538.

    PMID: 34325226
  24. 24

    Nonorgan manifestations of sarcoidosis.

    Tavee J, Culver D

    Current opinion in pulmonary medicine 2019; (25(5)):533-538 doi:10.1097/MCP.0000000000000597.

    PMID: 31365388
  25. 25

    Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes.

    Saketkoo LA, Russell AM, Jensen K, et al.

    Diagnostics (Basel, Switzerland) 2021; (11(6)) doi:10.3390/diagnostics11061089.

    PMID: 34203584
  26. 26

    Psychological burden associated with worse clinical outcomes in sarcoidosis.

    Sharp M, Brown T, Chen E, et al.

    BMJ open respiratory research 2019; (6(1)):e000467 doi:10.1136/bmjresp-2019-000467.

    PMID: 31673367
  27. 27

    Fatigue in Patients with Sarcoidosis in Denmark.

    Møller J, Hilberg O, Bendstrup E

    Lung 2023; (201(1)):103-110 doi:10.1007/s00408-023-00602-0.

    PMID: 36773043
  28. 28

    Assessment of Disease Burden Among Japanese Patients With Pulmonary Sarcoidosis: A Questionnaire-Based Study.

    Tomioka H, Sato H, Kanakubo M, et al.

    Cureus 2025; (17(10)):e94425 doi:10.7759/cureus.94425.

    PMID: 41234984

This page provides educational information on long-term sarcoidosis care and survivorship. It does not replace professional medical advice, monitoring, or treatment from your specialized healthcare team.

Stay up to date

Get notified when new research about Sarcoidosis is published.

No spam. Unsubscribe anytime.